(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.09%) $79.07
(5.02%) $2.03
(0.09%) $2 313.10
(0.66%) $26.93
(0.85%) $963.00
(-0.08%) $0.932
(-0.38%) $10.99
(-0.07%) $0.798
(-1.36%) $91.99
Live Chart Being Loaded With Signals
Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products...
Stats | |
---|---|
Šios dienos apimtis | 48 700.00 |
Vidutinė apimtis | 209 955 |
Rinkos kapitalizacija | 38.88B |
EPS | ¥0 ( 2024-02-07 ) |
Kita pelno data | ( ¥0 ) 2024-05-08 |
Last Dividend | ¥17.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 7.69 |
ATR14 | ¥0.880 (0.05%) |
Tūris Koreliacija
Fuji Pharma Co., Ltd. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Fuji Pharma Co., Ltd. Koreliacija - Valiuta/Žaliavos
Fuji Pharma Co., Ltd. Finansinės ataskaitos
Annual | 2023 |
Pajamos: | ¥40.89B |
Bruto pelnas: | ¥16.52B (40.39 %) |
EPS: | ¥141.35 |
FY | 2023 |
Pajamos: | ¥40.89B |
Bruto pelnas: | ¥16.52B (40.39 %) |
EPS: | ¥141.35 |
FY | 2022 |
Pajamos: | ¥35.43B |
Bruto pelnas: | ¥14.56B (41.10 %) |
EPS: | ¥110.98 |
FY | 2021 |
Pajamos: | ¥33.99B |
Bruto pelnas: | ¥14.75B (43.40 %) |
EPS: | ¥78.06 |
Financial Reports:
No articles found.
Fuji Pharma Co., Ltd. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥20.00 (N/A) |
¥0 (N/A) |
¥17.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥6.50 | 2010-03-29 |
Last Dividend | ¥17.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 28 | -- |
Total Paid Out | ¥321.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.43 | -- |
Div. Sustainability Score | 8.73 | |
Div.Growth Potential Score | 5.58 | |
Div. Directional Score | 7.16 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9760.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
8835.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
8285.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7673.T | Ex Dividend Junior | 2024-05-30 | Annually | 0 | 0.00% | |
6855.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6203.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
4929.T | Ex Dividend Junior | 2024-03-18 | Annually | 0 | 0.00% | |
4099.T | Ex Dividend Junior | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
3315.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
2384.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.122 | 1.500 | 7.57 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0598 | 1.200 | 8.01 | 9.61 | [0 - 0.3] |
returnOnEquityTTM | 0.123 | 1.500 | 9.74 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.458 | 0.800 | 7.71 | 6.17 | [1 - 3] |
quickRatioTTM | 0.610 | 0.800 | -1.120 | -0.896 | [0.8 - 2.5] |
cashRatioTTM | 0.0780 | 1.500 | -0.678 | -1.017 | [0.2 - 2] |
debtRatioTTM | 0.324 | -1.500 | 4.61 | -6.91 | [0 - 0.6] |
interestCoverageTTM | 20.55 | 1.000 | 3.50 | 3.50 | [3 - 30] |
operatingCashFlowPerShareTTM | 259.78 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 259.78 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.652 | -1.500 | 7.39 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.385 | 1.000 | 6.92 | 6.92 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0607 | 1.000 | -0.786 | -0.786 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.231 | 1.000 | 9.83 | 9.83 | [0.2 - 2] |
assetTurnoverTTM | 0.492 | 0.800 | -0.0514 | -0.0411 | [0.5 - 2] |
Total Score | 8.73 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 7.69 | 1.000 | 9.32 | 0 | [1 - 100] |
returnOnEquityTTM | 0.123 | 2.50 | 9.83 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 259.78 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.50 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 259.78 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.281 | 1.500 | -1.461 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.152 | 1.000 | 8.71 | 0 | [0.1 - 0.5] |
Total Score | 5.58 |
Fuji Pharma Co., Ltd.
Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women; in vitro diagnostics, acute medical care products, and curative medicines; and information regarding pharmaceuticals and health. Fuji Pharma Co., Ltd. was incorporated in 1965 and is headquartered in Tokyo, Japan.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.